A great deal of work can go into refining the content of a patient information leaflet – only for its readability to be weakened at the graphic design stage.
Because patients do not use a PIL as a Word document. They use the actual leaflet they take out of the medicine pack.
How information is presented can help them reach what they need quickly – or make even well-written content difficult to find and use.
Patients receive a leaflet, not a Word document
Regulatory Affairs rightly places considerable emphasis on content.
Is the leaflet aligned with the SmPC? Does it follow the appropriate QRD template? Is the information presented correctly?
But patients do not receive content in isolation.
They receive a finished document.
And they do not necessarily read it calmly from beginning to end. Often, they reach for the leaflet because they need a specific answer – sometimes at a moment of uncertainty or stress.
They may want to check the dose. They may be concerned about a possible side effect. They may need to know what to do in a particular situation.
At that point, it is not enough for the relevant information simply to be somewhere in the leaflet.
Patients need to be able to reach it quickly – precisely when they need it.
That is where graphic design stops being merely an aesthetic consideration.
Good content can lose readability through poor presentation
Information can be medically and regulatory correct and still be difficult to use.
The way it is presented influences how users perceive the structure of the document, where they direct their attention and how easily they navigate the leaflet.
Content and graphic design should therefore not be treated as two separate worlds.
Patients do not see “content” and “layout”. They see a leaflet.
When the design supports the logic of the information, the document is easier to use. When it works against that logic, even well-prepared content can lose some of its effectiveness.
“Content approved” does not always mean “leaflet ready”
This is an important distinction for Regulatory Affairs.
Content approval is a key milestone, but it does not yet tell us how the document will work in its final form.
European readability guidance refers to testing material that is representative of the leaflet that will actually be provided to users.
That makes sense.
If we want to assess whether patients can use a leaflet, we should assess the leaflet itself, rather than abstract content separated from the way it is presented.
That is why:
“The PIL content is final”
and
“The leaflet is ready”
do not necessarily describe the same stage.
Graphic design meets the PHARMBICON 3Z Method at the very first step
At PHARMBICON, we look at patient information through three consecutive stages:
FIND → UNDERSTAND → ACT
Graphic design already matters at the first:
FIND.
Before patients can understand information and act on it, they first need to be able to find it.
Good graphic design cannot guarantee that the content will be understood.
But even the best content has limited value if patients struggle to locate it.
Graphic design does not need to be “pretty”. It needs to help the information work
This is perhaps the most important distinction.
For patient information, aesthetics are not an end in themselves.
A leaflet may look modern and still be difficult to use. It may also be visually restrained while allowing users to reach the information they need efficiently.
So the right question is not:
“Does this leaflet look good?”
but:
“Does the way this leaflet is designed help patients use the information?”
That is much closer to what readability is really about.
Summary
The content of a leaflet and its graphic design serve different purposes, but patients experience them at the same time.
Good content is not enough if it is difficult to reach. Good graphic design cannot compensate for poor content.
Patients need both.
Graphic design is not decoration. It is part of how information reaches the patient.